Complete pathological response of bone metastasis in metastatic renal cell carcinoma treated with pembrolizumab plus lenvatinib after surgical debulking and palliative radiotherapy: a case report
Oct 2026· Drugs in Context· pp. 1· 1 citation· 20 references
TL;DR
The case of a 33-year-old female patient with clear cell mRCC who developed metastatic progression after undergoing curative-intent surgery, presenting with vertebral bone metastasis at C7 and peritoneal carcinomatosis is reported.
Abstract
Metastatic renal cell carcinoma (mRCC) presents with marked biological heterogeneity, and bone involvement is associated with aggressive disease and limited response to systemic therapies. We report the case of a 33-year-old female patient with clear cell mRCC who developed metastatic progression after undergoing curative-intent surgery, presenting with vertebral bone metastasis at C7 and peritoneal carcinomatosis. First-line treatment with pembrolizumab plus lenvatinib was initiated, leading to a deep and durable response. A radiological complete response was achieved at all metastatic sites, and subsequent surgery confirmed histological complete remission in the bone lesion. Pathologically documented complete responses in bone metastases from RCC are remarkably rare. This case highlights the potential of immune-checkpoint inhibitor–tyrosine kinase inhibitor combinations to induce profound responses even in unfavourable metastatic patterns and supports a multidisciplinary treatment strategy.
Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-complete-pathological-response-of-bone-metastasis-in-metastatic-renal-cell-carcinoma-treated-with-pembrolizumab-plus-lenvatinib-after-surgical-debulking-and-palliative-radio
This article is part of the Special Issue From evidence to the individual patient: pembrolizumab plus lenvatinib in real-world metastatic renal cell carcinoma: https://www.drugsincontext.com/special_issues/from-evidence-to-the-individual-patient-pembrolizumab-plus-lenvatinib-in-real-world-metastatic-renal-cell-carcinoma
Sarcomatoid dedifferentiation and bone metastases characterize an aggressive subset of metastatic renal cell carcinoma (mRCC) with a poor prognosis. Immune- checkpoint inhibitor combinations are the standard first-line therapy, whilst the role of deferred cytoreductive nephrectomy (dCN) remains debated. We report on th...
G. Novero, Isabella Cavaglià, L. Delsedime et al.· Drugs in Context· 1 citation
Background Hilar cholangiocarcinoma (hCCA) is an aggressive malignancy with limited therapeutic options and poor prognosis, particularly in patients with unresectable or metastatic disease. Although immune checkpoint inhibitors and targeted therapies have improved outcomes, resistance remains a major challenge. Here, w...
Peng Wang, Chen-Tao Zou, Wen-Di Liu et al.· Frontiers in Immunology· 0 citations
We report the case of a 65-year-old woman diagnosed with metastatic chromophobe renal cell carcinoma, classified as intermediate risk according to IMDC criteria, who presented with a large left renal mass, para-aortic lymphadenopathy and bilateral pulmonary nodules. First-line treatment with pembrolizumab plus lenvatin...
Laura Palumbo, M. Palladino, Malak Zarrar et al.· Drugs in Context· 1 citation
BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by aggressive disease behavior and limited responsiveness to conventional systemic therapy. Although BRAF/EGFR-targeted therapies have improved clinical outcomes, durable complete remission remains uncommon, particularly in microsatellite-stable (MS...
Rong Li, Yan-Ping Lin, Jiang-Yan Guo et al.· Anti-Cancer Drugs· 0 citations
This case demonstrates that even when HP-SCNEC abdominal lesions achieve deep remission through intensified immunotherapy combined with chemotherapy, patients remain at extremely high risk for early brain metastases, highlighting the “intracranial sanctuary” effect caused by the blood-brain barrier.
Jing Cui, Yu-Kai Gao· Frontiers in Medicine· 0 citations
Background Hepatocellular carcinoma (HCC) has a high incidence worldwide, and most patients are diagnosed at the intermediate or advanced stages; 10%–40% lose the opportunity for surgery due to concomitant vascular invasion. A triple-therapy regimen combining transarterial chemoembolization (TACE)/hepatic arterial infu...
Xiong-Xiong Han, Yao Pang, Shu-Lin Xu et al.· Journal of Hepatocellular Ca...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.